Literature DB >> 16964294

Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas.

J Zucman-Rossi1, S Benhamouche, C Godard, S Boyault, G Grimber, C Balabaud, A S Cunha, P Bioulac-Sage, C Perret.   

Abstract

Perturbations to the Wnt signaling pathway have been implicated in a large proportion of human hepatocellular carcinomas (HCCs). Activating beta-catenin mutations and loss of function mutations in Axin1 are thought to be functionally equivalent. We examined the Wnt pathway in HCC by comparing the expression of beta-catenin target genes and the level of beta-catenin-dependent transcriptional activation, in 45 HCC tumors and four cell lines. Among these samples, beta-catenin and AXIN1 were mutated in 20 and seven cases, respectively. We found a significant correlation between activated beta-catenin mutations and overexpression of mRNA for the target genes glutamine synthetase (GS), G-protein-coupled receptor (GPR)49 and glutamate transporter (GLT)-1 (P=0.0001), but not for the genes ornithine aminotransferase, LECT2, c-myc and cyclin D1. We also showed that GS is a good immunohistochemical marker of beta-catenin activation in HCC. However, we observed no induction of GS, GPR49 or GLT-1 in the five inactivated Axin1 tumors. Beta-catenin-dependent transcriptional activation in two Axin1-mutated HCC cell lines was much weaker than in beta-catenin-mutated cell lines. Our results strongly suggest that in HCC, contrary to expectation, the loss of function of Axin1 is not equivalent to the gain of function of beta-catenin. Our results also suggest that the tumor suppressor function of Axin1 in HCC may be related to another, non-Wnt pathway.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16964294     DOI: 10.1038/sj.onc.1209824

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  96 in total

1.  Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma.

Authors:  M Sherman; K Burak; J Maroun; P Metrakos; J J Knox; R P Myers; M Guindi; G Porter; J R Kachura; P Rasuli; S Gill; P Ghali; P Chaudhury; J Siddiqui; D Valenti; A Weiss; R Wong
Journal:  Curr Oncol       Date:  2011-10       Impact factor: 3.677

2.  Molecular subclasses of hepatocellular carcinoma predict sensitivity to fibroblast growth factor receptor inhibition.

Authors:  Benjamin Schmidt; Lan Wei; Danielle K DePeralta; Yujin Hoshida; Poh Seng Tan; Xiaochen Sun; Janelle P Sventek; Michael Lanuti; Kenneth K Tanabe; Bryan C Fuchs
Journal:  Int J Cancer       Date:  2015-11-09       Impact factor: 7.396

Review 3.  Beta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad.

Authors:  Kari Nichole Nejak-Bowen; Satdarshan P S Monga
Journal:  Semin Cancer Biol       Date:  2010-12-21       Impact factor: 15.707

4.  Pegylated interferon alpha targets Wnt signaling by inducing nuclear export of β-catenin.

Authors:  Michael D Thompson; Mohd Jamal Dar; Satdarshan P S Monga
Journal:  J Hepatol       Date:  2010-10-29       Impact factor: 25.083

Review 5.  Tumor suppressor and hepatocellular carcinoma.

Authors:  Juliette Martin; Jean-Francois Dufour
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

6.  The Effect of Selective c-MET Inhibitor on Hepatocellular Carcinoma in the MET-Active, β-Catenin-Mutated Mouse Model.

Authors:  Na Zhan; Adeola Adebayo Michael; Kaiyuan Wu; Gang Zeng; Aaron Bell; Junyan Tao; Satdarshan P Monga
Journal:  Gene Expr       Date:  2018-02-06

7.  Metabolic network-based stratification of hepatocellular carcinoma reveals three distinct tumor subtypes.

Authors:  Gholamreza Bidkhori; Rui Benfeitas; Martina Klevstig; Cheng Zhang; Jens Nielsen; Mathias Uhlen; Jan Boren; Adil Mardinoglu
Journal:  Proc Natl Acad Sci U S A       Date:  2018-11-27       Impact factor: 11.205

Review 8.  WNT signalling pathways as therapeutic targets in cancer.

Authors:  Jamie N Anastas; Randall T Moon
Journal:  Nat Rev Cancer       Date:  2013-01       Impact factor: 60.716

Review 9.  Wnt signaling in liver cancer.

Authors:  Yutaka Takigawa; Anthony M C Brown
Journal:  Curr Drug Targets       Date:  2008-11       Impact factor: 3.465

10.  Suppression of Hepatocellular Carcinoma by Inhibition of Overexpressed Ornithine Aminotransferase.

Authors:  Ehud Zigmond; Ami Ben Ya'acov; Hyunbeom Lee; Yoav Lichtenstein; Zvi Shalev; Yoav Smith; Lidya Zolotarov; Ehud Ziv; Rony Kalman; Hoang V Le; Hejun Lu; Richard B Silverman; Yaron Ilan
Journal:  ACS Med Chem Lett       Date:  2015-05-29       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.